Clinical trials: ITP - Immune Thrombocytopenia
Primary Immune Thrombocytopenia
Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)
This is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and initial efficacy of CM313 (SC) injection in patients with primary immune…
- Trial name
- NCT06594146
- Testing
- CM313 injection
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Keymed Biosciences Co.Ltd
Immune Thrombocytopenia
Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia
Hydroxychloroquine has been reported to have a clinically significant effect on the platelet count in systemic lupus thrombocytopenia. Its action may be due to its immune modulator effect.
- Trial name
- NCT03229746
- Testing
- Hydroxychloroquine, vincristine, azathioprine
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Immune Thrombocytopenia (ITP)
The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
This is a randomized, double blinded, placebo-controlled phase Ib clinical trial in adult patients with immune thrombocytopenia. Cross-over treatment will be allowed during the study.
- Trial name
- NCT03951623
- Testing
- HMPL-523
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Hutchison Medipharma Limited
Purpura, Thrombocytopenic, Idiopathic
Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
OBJECTIVES: I. Determine the response rate and response duration to rituximab in patients with immune thrombocytopenic purpura. II. Evaluate the toxicity associated with this treatment regimen in these patients. III.
- Trial name
- NCT00005652
- Testing
- rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Primary Immune Thrombocytopenia
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study. The primary objective is to evaluate the safety and efficacy of SG301 SC Injection in participants with ITP, while the secondary…
- Trial name
- NCT07710248
- Testing
- low dose group, high dose group
- Where
- 22 sites in China
- Volunteers
- 60 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Immune Thrombocytopenia With Positive ANA Antibodies
The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP
The goal of this clinical trial is to learn if hydroxychloroquine (HCQ) plus dexamethasone (DEX) works to treat primary immune thrombocytopenia with positive anti-nuclear antibodies in adults.
- Trial name
- NCT06479317
- Testing
- Hydroxychloroquine Oral Tablet, Dexamethasone oral
- Where
- 7 sites in China, Hong Kong and 1 more
- Volunteers
- 129 people
- Sponsor
- Yunfeng Cheng
Immune Thrombocytopenic Purpura
Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytopenia
The purpose of this study is to determine whether All-trans retinoic acid (ATRA) are effective in the treatment of refractory idiopathic thrombocytopenic purpura (RITP).
- Trial name
- ITP (NCT01668615)
- Testing
- all-trans-retinoid acid
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Suzhou Medical College
Immune Thrombocytopenic Purpura
Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10
The purpose of this study is to evaluate the efficacy, tolerability and safety of IgPro10 in the treatment of patients with chronic immune thrombocytopenic purpura (ITP).
- Trial name
- NCT00168038
- Testing
- Immunoglobulin Intravenous (Human)
- Where
- 17 sites in Germany, Italy and 4 more
- Volunteers
- 58 people
- Sponsor
- CSL Behring
Purpura, Thrombocytopaenic, Idiopathic
Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment
The main purpose of this study is to compare how one 50mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe liver problems.
- Trial name
- NCT00359463
- Testing
- eltrombopag
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Purpura, Thrombocytopaenic, Idiopathic
A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
A open-label, multi-center 2-year safety study to ascertain the baseline levels of bone marrow fibers in previously treated adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and to evaluate the long-term…
- Trial name
- NCT01098487
- Testing
- Eltrombopag olamine
- Where
- 34 sites in United States, Czechia and 9 more
- Volunteers
- 167 people
- Sponsor
- GlaxoSmithKline
Immune Thrombocytopenia Purpura
Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)
The primary objectives of this study are to assess the safety and tolerability of single rising doses of MK-8723 in healthy adult participants and adult participants with chronic immune thrombocytopenia purpura (ITP) and to…
- Trial name
- NCT01963260
- Testing
- MK-8723
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Immune Thrombocytopenia
Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
This is a prospective, open-label, single-arm, multicenter, Phase 4 study evaluating the efficacy and safety of PANZYGA in pediatric patients with chronic ITP.
- Trial name
- NCT03866798
- Testing
- Panzyga
- Where
- 8 sites in United States
- Volunteers
- 6 people
- Sponsor
- Octapharma
Immune Thrombocytopenia
The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Single-arm, open-lable, multicentre study to compare the efficacy and safety of atorvastatin, acetylcysteine plus danazol with danazol monotherapy in patients with corticosteroidresistant/relapsed ITP.
- Trial name
- NCT03460808
- Testing
- atorvastatin, Acetylcysteine, Danazol
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
ITP, Immune Thrombocytopenia
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
Evaluate patient characteristics, treatment patterns, clinical outcomes and safety of fostamatinib as second-line therapy in real-world clinical practice, for the treatment of ITP in adult patients who have an insufficient…
- Trial name
- NCT04904276
- Testing
- Fostamatinib
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Rigel Pharmaceuticals
Immune Thrombocytopenia
Use of Vitamin D as An Adjuvant Treatment in Children With Chronic Idiopathic Thrombocytopenic Purpura
Immune thrombocytopenia is an autoimmune disease in which platelets are targeted by the host immune system. Platelet depletion occurs when autoantibodies targeting glycoproteins (αIIb-β3 and GPIb) found on the surface of…
- Trial name
- MansouraU (NCT06073925)
- Testing
- VIT D
- Volunteers
- 30 people
- Sponsor
- Mansoura University
Nonneoplastic Condition
Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura
RATIONALE: Drugs, such as prednisone and dexamethasone, may change the immune system and be an effective treatment for primary immune thrombocytopenic purpura.
- Trial name
- ITP0207 (NCT00657410)
- Testing
- dexamethasone, prednisone, quality-of-life assessment
- Where
- 42 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Thrombocytopenia
French Adult Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is rare. First-line treatment is corticotherapy. Then, several second-line treatments (SLT) are available: splenectomy, off-label rituximab and thrombopoietin-receptor agonists since 2009.
- Trial name
- FAITH (NCT03429660)
- Testing
- Medical information
- Where
- France
- Volunteers
- 10,000 people
- Sponsor
- University Hospital, Toulouse
Purpura, Thrombocytopenic, Idiopathic
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
The purpose of this study is to determine whether Fostamatinib Disodium is safe and effective in the treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP).
- Trial name
- NCT00706342
- Testing
- Fostamatinib Disodium / R935788
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Rigel Pharmaceuticals
Childhood Chronic Immune Thrombocytopenia
The Role of Traditional Chinese Medicine in the Treatment of Chronic Childhood Immune Thrombocytopenia (ITP)
Immune thrombocytopenia (ITP) is an autoimmune disorder manifested as isolated low platelet count which results in a tendency for bleeding.
- Trial name
- NCT01226524
- Testing
- Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan
- Where
- Israel
- Volunteers
- 7 people
- Sponsor
- Hadassah Medical Organization
Immune Thrombocytopenia (ITP), ITP
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
- Conditions
- Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal
- Trial name
- NCT07043946
- Testing
- Budoprutug
- Where
- 20 sites in Bulgaria, Greece and 3 more
- Volunteers
- 24 people
- Sponsor
- Climb Bio, Inc.